Newer Biomarkers in Heart Failure

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The pathophysiology of heart failure is complex, and the list of biomarkers representing distinct pathophysiologic pathways is growing rapidly. This article focuses on some promising newer biomarkers that have contributed to a better understanding of pathophysiologic mechanisms involved in heart failure but for which less data are currently available: osteoprotegerin, galectin-3, cystatin C, chromogranin A, and the adipokines adiponectin, leptin, and resistin. Despite the intriguing early information from these newer markers, none is ready for routine clinical use. Much additional study is needed to determine how these biomarkers will fit into diagnostic and treatment algorithms for patients who have heart failure.

Original languageEnglish (US)
Pages (from-to)579-588
Number of pages10
JournalHeart Failure Clinics
Volume5
Issue number4
DOIs
StatePublished - Oct 2009

Fingerprint

Heart Failure
Biomarkers
Resistin
Galectin 3
Osteoprotegerin
Cystatin C
Chromogranin A
Adipokines
Adiponectin
Leptin
Therapeutics

Keywords

  • Adipokines
  • Biomarkers
  • Chromogranin A
  • Cystatins
  • Galectins
  • Heart failure
  • Osteoprotegerin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Newer Biomarkers in Heart Failure. / Gupta, Sachin; Drazner, Mark H; de Lemos, James A.

In: Heart Failure Clinics, Vol. 5, No. 4, 10.2009, p. 579-588.

Research output: Contribution to journalArticle

@article{73ef840cd5b1455b99210fddbabfc0c6,
title = "Newer Biomarkers in Heart Failure",
abstract = "The pathophysiology of heart failure is complex, and the list of biomarkers representing distinct pathophysiologic pathways is growing rapidly. This article focuses on some promising newer biomarkers that have contributed to a better understanding of pathophysiologic mechanisms involved in heart failure but for which less data are currently available: osteoprotegerin, galectin-3, cystatin C, chromogranin A, and the adipokines adiponectin, leptin, and resistin. Despite the intriguing early information from these newer markers, none is ready for routine clinical use. Much additional study is needed to determine how these biomarkers will fit into diagnostic and treatment algorithms for patients who have heart failure.",
keywords = "Adipokines, Biomarkers, Chromogranin A, Cystatins, Galectins, Heart failure, Osteoprotegerin",
author = "Sachin Gupta and Drazner, {Mark H} and {de Lemos}, {James A}",
year = "2009",
month = "10",
doi = "10.1016/j.hfc.2009.04.004",
language = "English (US)",
volume = "5",
pages = "579--588",
journal = "Heart Failure Clinics",
issn = "1551-7136",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Newer Biomarkers in Heart Failure

AU - Gupta, Sachin

AU - Drazner, Mark H

AU - de Lemos, James A

PY - 2009/10

Y1 - 2009/10

N2 - The pathophysiology of heart failure is complex, and the list of biomarkers representing distinct pathophysiologic pathways is growing rapidly. This article focuses on some promising newer biomarkers that have contributed to a better understanding of pathophysiologic mechanisms involved in heart failure but for which less data are currently available: osteoprotegerin, galectin-3, cystatin C, chromogranin A, and the adipokines adiponectin, leptin, and resistin. Despite the intriguing early information from these newer markers, none is ready for routine clinical use. Much additional study is needed to determine how these biomarkers will fit into diagnostic and treatment algorithms for patients who have heart failure.

AB - The pathophysiology of heart failure is complex, and the list of biomarkers representing distinct pathophysiologic pathways is growing rapidly. This article focuses on some promising newer biomarkers that have contributed to a better understanding of pathophysiologic mechanisms involved in heart failure but for which less data are currently available: osteoprotegerin, galectin-3, cystatin C, chromogranin A, and the adipokines adiponectin, leptin, and resistin. Despite the intriguing early information from these newer markers, none is ready for routine clinical use. Much additional study is needed to determine how these biomarkers will fit into diagnostic and treatment algorithms for patients who have heart failure.

KW - Adipokines

KW - Biomarkers

KW - Chromogranin A

KW - Cystatins

KW - Galectins

KW - Heart failure

KW - Osteoprotegerin

UR - http://www.scopus.com/inward/record.url?scp=67650588131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650588131&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2009.04.004

DO - 10.1016/j.hfc.2009.04.004

M3 - Article

C2 - 19631181

AN - SCOPUS:67650588131

VL - 5

SP - 579

EP - 588

JO - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 4

ER -